INFINITT North America Announces Collaboration with Brainreader A/S to Market Neuro AI for Brain Structure Analysis

Phillipsburg, NJ - INFINITT North America and Brainreader A/S announced today a wide ranging and unique partnership to expand and deepen the use of Brainreader's FDA cleared Neuroreader software. Neuroreader Report analyzes an MRI sequence to determine whether brain structures are abnormal and to what extent. It visualizes and quantifies 45 individual brain structures in less than ten minutes after Magnetic Resonance Imaging.

"We are very excited about the INFINITT/Brianreader partnership," said Brainreader CEO Mads Fiig. "This relationship combines forward looking science with an extremely useful tool for clinicians. Omar Rocha, our U.S. President, has been instrumental in building this wide embrace of the INFINITT customer base."

INFINITT North America, an award-winning developer of enterprise imaging solutions for healthcare, will utilize Neuroreader throughout its U.S. operations, focusing on Hippocampal lobe volume, atrophies and trends as well as applying data from Brainreader's advanced diversified normative datasets. Brainreader's expanding AI technology brings objectivity into clinical practice, detecting anomalous brain patterns, and is a proven guide for clinical decision making.

"AI and rigorously applied clinical science have resulted in new uses for brain data as a clinical tool, promoting earlier treatments, and more accurate diagnoses", said David Smarro, INFINITT N.A. President and CEO. "Neuroreader speeds up the process, increases accuracy and will improve clinical outcomes."

"INFINITT's large North American customer base provides an opportunity for both companies to uniquely contribute" said Omar Rocha, U.S. Brainreader President, "to improving doctors’ speed, accuracy, and depth of understanding as well as providing actionable aid in diagnosis and treatment."

About INFINITT North America INFINITT North America is the North American business unit of INFINITT Healthcare, a global company with more than 6500 installations in 55 countries. INFINITT's enterprise imaging solutions include INFINITT Healthcare Platform (VNA), RIS, PACS, Mammography PACS, Cardiology Suite, Digital Pathology PACS, RT PACS, Dental PACS, Ophthalmology PACS, an AI Integration Platform and an Advanced Visualization software platform. For more information, call 877-387-6960 or visit infinittna.com.

Around the web

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.